Literature DB >> 9605043

One-year outcomes of diabetic versus nondiabetic patients with non-Q-wave acute myocardial infarction treated with percutaneous transluminal coronary angioplasty.

M S Gowda1, J L Vacek, D Hallas.   

Abstract

Risk factors and outcomes associated with non-Q-wave myocardial infarction (MI) in diabetics and nondiabetics were analyzed for 376 consecutive patients, 77 with diabetes (20%) and 299 nondiabetics (80%), who had non-Q-wave MI and had percutaneous transluminal coronary angioplasty (PTCA) performed before discharge from hospital during the period from January 1992 to February 1996. Diabetics were slightly older (64 +/- 10 years vs 61 +/- 12 years, p <0.053), had more prior coronary artery bypass grafting (CABG) surgery (27% vs 12%, p <0.001), and hypertension (77% vs 49%, p <0.001). There was no significant difference in unstable angina, saphenous vein graft PTCA, single versus multiple vessel disease, or history of MI. PTCA success rates for diabetics versus nondiabetics were similar (96% vs 97%, p = NS). In-hospital complications such CABG, recurrent MI, repeat PTCA, stroke, and death were not statistically significant between the 2 groups. At 1-year follow-up, survival in diabetics (92%) was similar to nondiabetics (94%, p = NS), although event-free survival (PTCA, CABG, MI, death) was worse in diabetics (55% vs 67% for nondiabetics, p <0.05). Although diabetic patients with non-Q-wave MI represent a cohort with more risk factors for poor outcome, aggressive in-hospital revascularization with PTCA results in an excellent short-term outcome as well as 1-year survival similar to the nondiabetic patients. However, total events at 1-year follow-up are more common in the diabetic patients, suggesting that more aggressive screening and therapy in follow-up may be warranted, and that a diabetic with non-Q-wave MI will require increased utilization of cardiovascular resources in the first year after the event.

Entities:  

Mesh:

Year:  1998        PMID: 9605043     DOI: 10.1016/s0002-9149(98)00117-9

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  4 in total

Review 1.  Percutaneous coronary intervention in diabetics.

Authors:  Juhana Karha; Deepak L Bhatt
Journal:  Rev Endocr Metab Disord       Date:  2004-08       Impact factor: 6.514

2.  Impact of diabetes mellitus on long-term outcome after unstable angina and non-ST-segment elevation myocardial infarction treated with a very early invasive strategy.

Authors:  C Müller; F J Neumann; M Ferenc; A P Perruchoud; H J Büttner
Journal:  Diabetologia       Date:  2004-07-03       Impact factor: 10.122

3.  Efficacy and safety of abciximab in diabetic patients who underwent percutaneous coronary intervention with thienopyridines loading: a meta-analysis.

Authors:  Yihua Wu; Yu Shi; Han Wu; Chang Bian; Qian Tang; Geng Xu; Jun Yang
Journal:  PLoS One       Date:  2011-06-03       Impact factor: 3.240

4.  Long-term clinical benefits of a platelet glycoprotein IIb/IIIa receptor blocker, abciximab (ReoPro), in high-risk diabetic patients undergoing percutaneous coronary intervention.

Authors:  Doo Sun Sim; Myung Ho Jeong; Weon Kim; Jay Young Rhew; Ju Hyup Yum; Ju Han Kim; Jeong Gwan Cho; Young Keun Ahn; Jong Chun Park; Byoung Hee Ahn; Sang Hyung Kim; Jung Chaee Kang
Journal:  Korean J Intern Med       Date:  2003-09       Impact factor: 2.884

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.